12010 related articles for article (PubMed ID: 11374804)
21. Cripto-1 expression in uveal melanoma: an immunohistochemical study.
Mallikarjuna K; Vaijayanthi P; Krishnakumar S
Exp Eye Res; 2007 Jun; 84(6):1060-6. PubMed ID: 17412323
[TBL] [Abstract][Full Text] [Related]
22. TGF-beta in uveal melanoma.
Esser P; Grisanti S; Bartz-Schmidt K
Microsc Res Tech; 2001 Feb; 52(4):396-400. PubMed ID: 11170298
[TBL] [Abstract][Full Text] [Related]
23. Expression of cyclin-D1 in uveal malignant melanoma.
Errico ME; Staibano S; Tranfa F; Bonavolonta G; Lo Muzio L; Somma P; Lucariello A; Mansueto G; D'Aponte A; Ferrara G; De Rosa G
Anticancer Res; 2003; 23(3B):2701-6. PubMed ID: 12894561
[TBL] [Abstract][Full Text] [Related]
24. Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) in posterior uveal melanoma: correlation with clinical and histological survival markers.
Khatib N; Pe'er J; Ortenberg R; Schachter J; Frenkel S; Markel G; Amer R
Invest Ophthalmol Vis Sci; 2011 Dec; 52(13):9368-72. PubMed ID: 22039239
[TBL] [Abstract][Full Text] [Related]
25. Differential expression of fourteen proteins between uveal melanoma from patients who subsequently developed distant metastases versus those who did Not.
Linge A; Kennedy S; O'Flynn D; Beatty S; Moriarty P; Henry M; Clynes M; Larkin A; Meleady P
Invest Ophthalmol Vis Sci; 2012 Jul; 53(8):4634-43. PubMed ID: 22570344
[TBL] [Abstract][Full Text] [Related]
26. [Expression of P53 protein in cutaneous melanoma].
Casazza S; Gambini C; Tunesi G; Rovida S; Caruso F; Pastorino A; Canepa M
Pathologica; 1993; 85(1097):335-42. PubMed ID: 8233650
[TBL] [Abstract][Full Text] [Related]
27. The relationships between p53 protein expression and the clinicopathological features in the uveal melanomas.
Hussein MR
Cancer Biol Ther; 2005 Jan; 4(1):57-9. PubMed ID: 15662123
[TBL] [Abstract][Full Text] [Related]
28. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target.
All-Ericsson C; Girnita L; Seregard S; Bartolazzi A; Jager MJ; Larsson O
Invest Ophthalmol Vis Sci; 2002 Jan; 43(1):1-8. PubMed ID: 11773005
[TBL] [Abstract][Full Text] [Related]
29. Status of the NF1 tumor suppressor locus in uveal melanoma.
Foster WJ; Fuller CE; Perry A; Harbour JW
Arch Ophthalmol; 2003 Sep; 121(9):1311-5. PubMed ID: 12963615
[TBL] [Abstract][Full Text] [Related]
30. Bcl-2 expression in primary uveal melanoma.
Sulkowska M; Famulski W; Bakunowicz-Lazarczyk A; Chyczewski L; Sulkowski S
Tumori; 2001; 87(1):54-7. PubMed ID: 11669559
[TBL] [Abstract][Full Text] [Related]
31. Expression of vascular endothelial growth factor a, matrix metalloproteinase 9 and extravascular matrix patterns in iris and ciliary body melanomas.
Sahin A; Kiratli H; Tezel GG; Soylemezoglu F; Bilgic S
Ophthalmic Res; 2007; 39(1):40-4. PubMed ID: 17164576
[TBL] [Abstract][Full Text] [Related]
32. Expression of haematogenous and lymphogenous chemokine receptors and their ligands on uveal melanoma in association with liver metastasis.
Dobner BC; Riechardt AI; Joussen AM; Englert S; Bechrakis NE
Acta Ophthalmol; 2012 Dec; 90(8):e638-44. PubMed ID: 23164171
[TBL] [Abstract][Full Text] [Related]
33. GPNMB expression in uveal melanoma: a potential for targeted therapy.
Williams MD; Esmaeli B; Soheili A; Simantov R; Gombos DS; Bedikian AY; Hwu P
Melanoma Res; 2010 Jun; 20(3):184-90. PubMed ID: 20375921
[TBL] [Abstract][Full Text] [Related]
34. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
35. Flow cytometric analysis of p53 oncoprotein expression in cutaneous melanoma.
Ross DA; Wilson GD
Br J Surg; 1997 Jun; 84(6):803-7. PubMed ID: 9189093
[TBL] [Abstract][Full Text] [Related]
36. Comparative study of p63 and p53 expression in tissue microarrays of malignant melanomas.
Brinck U; Ruschenburg I; Di Como CJ; Buschmann N; Betke H; Stachura J; Cordon-Cardo C; Korabiowska M
Int J Mol Med; 2002 Dec; 10(6):707-11. PubMed ID: 12429996
[TBL] [Abstract][Full Text] [Related]
37. Abnormalities of the transforming growth factor-beta pathway in ocular melanoma.
Myatt N; Aristodemou P; Neale MH; Foss AJ; Hungerford JL; Bhattacharya S; Cree IA
J Pathol; 2000 Dec; 192(4):511-8. PubMed ID: 11113869
[TBL] [Abstract][Full Text] [Related]
38. Aberrant expression of p53 gene product in malignant melanoma.
Rhim KJ; Hong SI; Hong WS; Lee SY; Lee DS; Jang JJ
J Korean Med Sci; 1994 Oct; 9(5):376-81. PubMed ID: 7702785
[TBL] [Abstract][Full Text] [Related]
39. HSP-27 protein expression in uveal melanoma: correlation with predicted survival.
Jmor F; Kalirai H; Taktak A; Damato B; Coupland SE
Acta Ophthalmol; 2012 Sep; 90(6):534-9. PubMed ID: 21114636
[TBL] [Abstract][Full Text] [Related]
40. Expression of vascular endothelial growth factor in uveal melanoma is independent of 6p21-region copy number.
Abdel-Rahman MH; Craig EL; Davidorf FH; Eng C
Clin Cancer Res; 2005 Jan; 11(1):73-8. PubMed ID: 15671530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
